Chemotherapy of Mycoplasma Infections

Team Leader: Florence Tardy (France)

Vision of the IRPCM chemotherapy group:
- Ascertain and reduce antimicrobial resistance levels in mollicutes to protect global human and animals for the future
- Coordinating international agreed standards for MIC of mollicute species
- Mapping global resistance of mollicutes of human and veterinary importance
- Reducing unnecessary use of antimicrobials and promoting good stewardship
- Understanding the molecular mechanisms of resistance
- Evaluation of new and alternative agents

Current Goals:
- To standardize veterinary mycoplasma antimicrobial sensitivity testing, including control strains and methodology like it was done for human mycoplasmas.
- To continue work on molecular determinants of antimicrobial resistance
- Identifying breakpoints
- Epidemiological surveillance
- Monitoring of antimicrobial resistance
- Development of the molecular assay to track antimicrobial resistance in the real-time
- Molecular typing of strains with different susceptibility
- Evaluation of new and alternative chemotherapeutic agents